Literature DB >> 15772686

Lentiviral vector-mediated gene transfer in adult mouse photoreceptors is impaired by the presence of a physical barrier.

O Grüter1, C Kostic, S V Crippa, M-T R Perez, L Zografos, D F Schorderet, F L Munier, Y Arsenijevic.   

Abstract

Gene transfer offers a substantial promise for the therapy of degenerative ocular diseases. Lentiviral vectors have the ability to efficiently transduce murine photoreceptors during the first days of life, but they are poorly effective on photoreceptors during adulthood. Here, we studied whether a physical barrier was responsible for this impairment. Previous studies have described the capacity of enzymes, such as chondroitinase ABC and neuraminidase X, to modify the structure of the interphotoreceptor matrix (IPM) when subretinally injected. Considering the IPM as a physical barrier that may decrease photoreceptor transduction, we injected different enzymes into the subretinal space of the adult mouse simultaneously with the lentiviral vector preparation, to increase viral transduction by fragilizing the IPM. Subretinal injection of neuraminidase X and chondroitinase ABC induces modifications in the IPM by, respectively, revealing or decreasing peanut agglutinin sites on photoreceptors. The simultaneous subretinal injection of neuraminidase X with a lentiviral vector driving the expression of a reporter gene in the photoreceptors increases the number of transduced cells significantly (around five-fold). After the enzyme treatment, the diffusion of the vector between the pigmented epithelium and the photoreceptors appears to facilitate the lentiviral vector transduction. Such approach targeting the IPM may help to design new strategies to improve gene delivery into the adult photoreceptors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15772686     DOI: 10.1038/sj.gt.3302485

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  30 in total

Review 1.  A perspective on the role of the extracellular matrix in progressive retinal degenerative disorders.

Authors:  Muayyad R Al-Ubaidi; Muna I Naash; Shannon M Conley
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-12-17       Impact factor: 4.799

Review 2.  Gene Therapy for the Retinal Degeneration of Usher Syndrome Caused by Mutations in MYO7A.

Authors:  Vanda S Lopes; David S Williams
Journal:  Cold Spring Harb Perspect Med       Date:  2015-01-20       Impact factor: 6.915

Review 3.  Gene therapy of inherited retinopathies: a long and successful road from viral vectors to patients.

Authors:  Pasqualina Colella; Alberto Auricchio
Journal:  Hum Gene Ther       Date:  2012-08       Impact factor: 5.695

4.  Changes in adeno-associated virus-mediated gene delivery in retinal degeneration.

Authors:  Kathleen D Kolstad; Deniz Dalkara; Karen Guerin; Meike Visel; Natalie Hoffmann; David V Schaffer; John G Flannery
Journal:  Hum Gene Ther       Date:  2010-05       Impact factor: 5.695

5.  Transduction of photoreceptors with equine infectious anemia virus lentiviral vectors: safety and biodistribution of StarGen for Stargardt disease.

Authors:  Katie Binley; Peter Widdowson; Julie Loader; Michelle Kelleher; Sharifah Iqball; Georgina Ferrige; Jackie de Belin; Marie Carlucci; Diana Angell-Manning; Felicity Hurst; Scott Ellis; James Miskin; Alcides Fernandes; Paul Wong; Rando Allikmets; Christopher Bergstrom; Thomas Aaberg; Jiong Yan; Jian Kong; Peter Gouras; Annick Prefontaine; Mark Vezina; Martin Bussieres; Stuart Naylor; Kyriacos A Mitrophanous
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-06-12       Impact factor: 4.799

Review 6.  Promising and delivering gene therapies for vision loss.

Authors:  Livia S Carvalho; Luk H Vandenberghe
Journal:  Vision Res       Date:  2014-08-02       Impact factor: 1.886

7.  Mid-stage intervention achieves similar efficacy as conventional early-stage treatment using gene therapy in a pre-clinical model of retinitis pigmentosa.

Authors:  Katherine J Wert; Javier Sancho-Pelluz; Stephen H Tsang
Journal:  Hum Mol Genet       Date:  2013-09-18       Impact factor: 6.150

8.  Correction of the disease phenotype in the mouse model of Stargardt disease by lentiviral gene therapy.

Authors:  J Kong; S-R Kim; K Binley; I Pata; K Doi; J Mannik; J Zernant-Rajang; O Kan; S Iqball; S Naylor; J R Sparrow; P Gouras; R Allikmets
Journal:  Gene Ther       Date:  2008-05-08       Impact factor: 5.250

9.  Genetic Rescue Reverses Microglial Activation in Preclinical Models of Retinitis Pigmentosa.

Authors:  Lijuan Zhang; Xuan Cui; Ruben Jauregui; Karen Sophia Park; Sally Justus; Yi-Ting Tsai; Jimmy K Duong; Chun-Wei Hsu; Wen-Hsuan Wu; Christine L Xu; Chyuan-Sheng Lin; Stephen H Tsang
Journal:  Mol Ther       Date:  2018-06-21       Impact factor: 11.454

Review 10.  Gene therapy for retinal disease.

Authors:  Michelle E McClements; Robert E MacLaren
Journal:  Transl Res       Date:  2013-01-08       Impact factor: 7.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.